Mar 04, 2024 / 05:50PM GMT
Stephen Michael Scala - TD Cowen, Research Division - MD & Senior Research Analyst
Well, Good afternoon. We're delighted to have Sanofi with us at Cowen's 44th Annual Healthcare Conference, representing the company is Naimish Patel, who is Global Head of Development for immunology and inflammation and Erik Wallström, who is Global Head of Development for Neurology. There's so much going on in these areas. So we have a lot to cover, and we're going to jump right in.
Questions and Answers:
Stephen Michael Scala - TD Cowen, Research Division - MD & Senior Research AnalystSo let's start out with the immunology and inflammation area. Dupixent is a phenomenal drug. So what unmet need in patient subgroups either for asthma or atopic dermatitis are not well served today that still represent opportunity for Sanofi?
Naimish Patel - Sanofi - Head of Global Development, Immunology & Inflammation Therapeutic Area
Sure. Thanks, Steve. Happy to be here today. I can start with atopic dermatitis. Its a huge disease
Trustpilot
